| 1 |
钱桂生. 肺癌不同病理类型发病率的变化情况及原因[J/CD]．中华肺部疾病杂志(电子版), 2011, 4(1):1-6.
|
| 2 |
Maione P, Rossi A, Sacco PC, et al. Advance in chemotherapy in advanced non-small-cell Lung cancer[J]. Expert Opin Pharmacother, 2010, 11(18):2997-3007.
|
| 3 |
Diaz LA Jr, Bardelli A. Liquid Biopsies: Genotyping circulating tumor DNA[J]. J Clin Oncol, 2014, 32(6):579-586.
|
| 4 |
Yoon KA, Park S, Lee SH, et al. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls[J]. J Mol Diagn, 2009, 11(3):182-185.
|
| 5 |
Heitzer E, Auer M, Hoffmann EM, et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer[J]. Int J Cancer, 2013, 133(2):346-356.
|
| 6 |
Nakao M, Muramatsu H, Sone K, et al. Epidermal growth factor receptor-tyrosine kinase inhibitors for non-small-cell lung cancer patients aged 80 years or older: a retrospective analysis[J]. Mol Clin Oncol, 2015, 3(2):403-407.
|
| 7 |
Shao ZM, Nguyen M. Tumor-specific DNA in plasma of breast cancer patients[J]. Anti-cancer Drngs, 2002, 13(4):353-357.
|
| 8 |
Lee HS, Hwang SM, Kim TS, et al. Circulating methylated septin 9 nucleic Acid in the plasma of patients with gastrointestinal cancer in the stomach and colon[J]. Transl Oncol, 2013, 6(3):290-296.
|
| 9 |
Wu Y, Du X, Xue C, et al. Quantification of serum SOX2 DNA with FQ-PCR potentially provides a diagnostic biomarker for lung cancer[J]. Med Oncol, 2013, 30(4):737.
|
| 10 |
Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage[J]. Nat Med, 2014, 20(5):552-558.
|
| 11 |
Ulivi P, Mercatali L, Casoni GL, et al. Multiple marker detection in peripheral blood for NSCLC diagnosis[J]. PLoS One, 2013, 8(2):e57401.
|
| 12 |
Lebofsky R, Decraene C, Bernard V, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types[J]. Mol Oncol, 2015, 9(4):783-790.
|
| 13 |
Szpechcinski A, Chorostowska-Wynimko J, Struniawski R, et al. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease[J]. Br J Cancer, 2015, 113(3):476-483.
|
| 14 |
邓水秋，欧阳学农，余宗阳，等. 晚期非小细胞肺癌血清游离DNA水平变化及意义[J]. 山东医药，2013, 53(30):6-8.
|
| 15 |
Madhavan D, Wallwiener M, Bents, et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis[J]. Breast Cancer Res Treat, 2014, 146(1):163-174.
|
| 16 |
Perrone F, Lampis A, Bertan C, et al. Circulating free DNA in a screening program for early colorectal cancerdetection[J]. Tumori, 2014, 100(2):115-121.
|
| 17 |
Battaglia P, Baritono E, Remo A, et al. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer[J]. Tumori, 2014, 100(2):122-127.
|
| 18 |
Tabernero J, Lenz HJ, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial[J]. Lancet Oncol, 2015, 16(8):937-948.
|
| 19 |
Spindler KL, Pallisgaard N, Andersen RF, et al. Changes in mutational status during third-line treatment for metastatic colorectal cancer-results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma[J]. Int J Cancer, 2014, 135(9):2215-2222.
|
| 20 |
Tabernero J, Lenz HJ, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial[J]. Lancet Oncol, 2015，16(8):937-948.
|